Efficacy and safety of the sirolimus-eluting stent versus the zotarolimus-eluting stent versus the paclitaxel-eluting stent
분야
의약학 > 내과학
저자
임철환 , 강원유 , 김연화 , 안혜미 , 황선호 , 김원 , 김완 , 홍영준 , 안영근 , 정명호 , 강정채
발행기관
대한내과학회
간행물정보
대한내과학회 추계학술발표논문집 2011년, 제2011권 제1호, 148(총1쪽)
파일형식
42846446.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Background and Objectives: Drug-eluting stents has been used to treat in patients with coronary artery diseases and shown to reduce rate of restenosis. We compared the efficacy and safety of the sirolimus-eluting stent (SES) versus the zotarolimus-eluting stent (ZES) versus the paclitaxel-eluting stent (PES) in patients with acute coronary syndromes. Methods: A postspective, multicenter, randomized trial was conducted to evaluate the safety and efficacy of SES (n=2357), ZES (n=283) and PES (n=1771) in 4423 patients undergoing primary percutaneous revascularization. The primary end point was composite of major adverse cardiac events at 6 months and 12 months: all-cause death, cardiac death, myocardial infarction and clinically driven target vessel revascularization. Results: At 6 months, the primary endpoint had occurred in a lower patients treated with SES than ZES (8.7% vs. 17%, HR 0.46, 95% CI 0.33-0.65, p<0.001), SES than PES (8.7% vs. 11.3%, HR 0.74, 95% CI 0.60-0.91, p=0.006) and higher patients treated with ZES than PES (17% vs. 11.3%, HR 1.61, 95% CI 1.14-2.25, p=0.005). At 12 months follow-up, this difference was similar results. SES vs. ZES (11.9% vs. 21.4%, HR 0.49, 95% CI 0.36-0.67, p<0.001), SES vs. PES (11.9% vs. 14.8%, HR 0.78, 95% CI 0.65-0.93, p=0.007), ZES vs. PES (21.4% vs. 14.8%, HR 1.57, 95% CI 1.15-2.13, p=0.004). All cause-motality at 12 months was SES vs. ZES (2.7% vs. 6.5%, HR 0.40, 95% CI 0.23-0.68, p<0.001), SES vs. PES (6.5% vs. 3.8%, HR 1.75, 95% CI 1.03-2.97, p=0.03), ZES vs. PES (2.7% vs. 3.8%, HR 0.71, 95% CI 0.50-1.00, p=0.53). Conclusion: Compared with ZES and PES, SES had superior clinical outcome.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.